NO953329L - Recombinant viruses and their use in gene therapy for the treatment of eye diseases - Google Patents
Recombinant viruses and their use in gene therapy for the treatment of eye diseasesInfo
- Publication number
- NO953329L NO953329L NO953329A NO953329A NO953329L NO 953329 L NO953329 L NO 953329L NO 953329 A NO953329 A NO 953329A NO 953329 A NO953329 A NO 953329A NO 953329 L NO953329 L NO 953329L
- Authority
- NO
- Norway
- Prior art keywords
- eye diseases
- treatment
- gene therapy
- recombinant viruses
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The use of defective recombinant adenoviruses containing an inserted gene for preparing a pharmaceutical useful for treating eye diseases is disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9302438A FR2702152B1 (en) | 1993-03-03 | 1993-03-03 | Recombinant viruses and their use in gene therapy. |
PCT/FR1994/000220 WO1994020146A1 (en) | 1993-03-03 | 1994-02-28 | Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
NO953329L true NO953329L (en) | 1995-08-24 |
NO953329D0 NO953329D0 (en) | 1995-08-24 |
NO319571B1 NO319571B1 (en) | 2005-08-29 |
Family
ID=9444602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19953329A NO319571B1 (en) | 1993-03-03 | 1995-08-24 | Use of a defective, recombinant adenovirus. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0687184B1 (en) |
JP (1) | JP3835809B2 (en) |
AT (1) | ATE220923T1 (en) |
AU (1) | AU693782B2 (en) |
CA (1) | CA2154355A1 (en) |
DE (1) | DE69431046T2 (en) |
DK (1) | DK0687184T3 (en) |
ES (1) | ES2181710T3 (en) |
FR (1) | FR2702152B1 (en) |
HU (1) | HU218900B (en) |
NO (1) | NO319571B1 (en) |
NZ (1) | NZ262135A (en) |
PT (1) | PT687184E (en) |
WO (1) | WO1994020146A1 (en) |
ZA (1) | ZA941426B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
FR2717823B1 (en) * | 1994-03-23 | 1996-04-26 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
IL113052A0 (en) * | 1994-03-23 | 1995-06-29 | Rhone Poulenc Rorer Sa | Recombinant viruses, their preparation and their use in gene therapy |
FR2726575B1 (en) * | 1994-11-09 | 1996-12-20 | Rhone Poulenc Rorer Sa | RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY |
FR2717824B1 (en) | 1994-03-25 | 1996-04-26 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
FR2718150B1 (en) | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
US6489305B1 (en) | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
ATE303820T1 (en) * | 1999-12-30 | 2005-09-15 | Aventis Pharma Sa | USE OF A VECTOR ENCODING AN ANTI-ANGIogenic FACTOR FOR THE TREATMENT OF CORNEA VASCULARIZATION |
FR2803207B1 (en) * | 1999-12-30 | 2004-04-30 | Aventis Pharma Sa | USE OF A VECTOR COMPRISING A NUCLEIC ACID ENCODING AN ANTI-ANGIOGENIC FACTOR FOR THE TREATMENT OF CORNEAL NEOVASCULARIZATIONS |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
CN101507822B (en) | 2003-11-24 | 2012-06-06 | 坎吉有限公司 | Reduction of dermal scarring |
EP1804835B9 (en) | 2004-09-13 | 2010-09-29 | Genzyme Corporation | Multimeric constructs |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | Vegf antagonist compositions and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002551A2 (en) * | 1988-09-13 | 1990-03-22 | Biosource Genetics Corporation | Prophylaxis and treatment of nervous system diseases with melanin |
JPH06506599A (en) * | 1991-04-05 | 1994-07-28 | エディソン アニマル バイオテクノロジー センター,オハイオ ユニバーシティー | Inhibition of retroviruses by antisense nucleic acids complementary to packaging sequences |
-
1993
- 1993-03-03 FR FR9302438A patent/FR2702152B1/en not_active Expired - Fee Related
-
1994
- 1994-02-28 AU AU61444/94A patent/AU693782B2/en not_active Ceased
- 1994-02-28 DE DE69431046T patent/DE69431046T2/en not_active Expired - Fee Related
- 1994-02-28 NZ NZ262135A patent/NZ262135A/en unknown
- 1994-02-28 WO PCT/FR1994/000220 patent/WO1994020146A1/en active IP Right Grant
- 1994-02-28 EP EP94908383A patent/EP0687184B1/en not_active Expired - Lifetime
- 1994-02-28 AT AT94908383T patent/ATE220923T1/en not_active IP Right Cessation
- 1994-02-28 JP JP51965094A patent/JP3835809B2/en not_active Expired - Fee Related
- 1994-02-28 PT PT94908383T patent/PT687184E/en unknown
- 1994-02-28 HU HU9502573A patent/HU218900B/en unknown
- 1994-02-28 DK DK94908383T patent/DK0687184T3/en active
- 1994-02-28 CA CA002154355A patent/CA2154355A1/en not_active Abandoned
- 1994-02-28 ES ES94908383T patent/ES2181710T3/en not_active Expired - Lifetime
- 1994-03-01 ZA ZA941426A patent/ZA941426B/en unknown
-
1995
- 1995-08-24 NO NO19953329A patent/NO319571B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO319571B1 (en) | 2005-08-29 |
NZ262135A (en) | 2000-12-22 |
DE69431046D1 (en) | 2002-08-29 |
AU6144494A (en) | 1994-09-26 |
EP0687184B1 (en) | 2002-07-24 |
ATE220923T1 (en) | 2002-08-15 |
HU9502573D0 (en) | 1995-10-30 |
FR2702152A1 (en) | 1994-09-09 |
CA2154355A1 (en) | 1994-09-15 |
DK0687184T3 (en) | 2002-10-28 |
ZA941426B (en) | 1994-10-04 |
EP0687184A1 (en) | 1995-12-20 |
HU218900B (en) | 2000-12-28 |
HUT73215A (en) | 1996-06-28 |
NO953329D0 (en) | 1995-08-24 |
FR2702152B1 (en) | 1995-05-24 |
AU693782B2 (en) | 1998-07-09 |
WO1994020146A1 (en) | 1994-09-15 |
JP3835809B2 (en) | 2006-10-18 |
PT687184E (en) | 2002-12-31 |
DE69431046T2 (en) | 2003-02-13 |
ES2181710T3 (en) | 2003-03-01 |
JPH08509208A (en) | 1996-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO953329D0 (en) | Recombinant viruses and their use in gene therapy for the treatment of eye diseases | |
FR2705361B1 (en) | Viral vectors and use in gene therapy. | |
ATE255128T1 (en) | PEPTIDE-IMMITTING SUBSTANCES IN CANCER THERAPY | |
AU586860B2 (en) | Therapeutical application of phosphonylmethoxyalkyl adenines | |
ATE254926T1 (en) | USE OF A CONSENSUS INTERFERON TO REDUCE ADVERSE EFFECTS IN THE INTERFERON TREATMENT OF VIRAL HEPATITES. | |
ATE380548T1 (en) | USE OF P53 INHIBITORS FOR THE TREATMENT OF ADVERSE SYMPTOMS OF CANCER THERAPY | |
ATE304058T1 (en) | RECOMBINANT MVA VIRUSES AND THEIR USE | |
DK0668763T3 (en) | Use of Phenserin in the manufacture of drugs for the treatment of cognitive disorders | |
NO883896L (en) | PROCEDURE FOR PREPARING CYTKINERMINED HUMAN IMMUNGLOBULIN CONJUGATES. | |
DE3877529D1 (en) | MANUFACTURE OF HIGHLY-LOST HUMAN FACTOR IX AND OTHER PLASMA PROTEIN CONCENTRATE AND THEIR THERAPEUTIC USE. | |
DK19488A (en) | RADIATION SYSTEM FOR USE IN MEDICAL TREATMENT OF NOSE AND NECK PASSAGES | |
DE69629570D1 (en) | 3'UTR OF THE HUMAN PROHIBITIN GENE | |
Dhillon et al. | Local anaesthetic and vasoconstrictor agents used in ENT | |
Dhillon et al. | Photodynamic therapy | |
MX9706569A (en) | Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy. |